Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single-dose Study of Apraglutide in Healthy Japanese Adults
jRCT2031220579Phase 1Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of apraglutide in short bowel syndrome (SBS) and intestinal failure (IF) (3 arms), sponsored by Asahi Kasei Corporation. Primary endpoint: Plasma concentration of apraglutide. Started Mar 2023; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on jRCT2031220579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220579.